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In Brief Royal et al. demonstrate that migraineassociated frameshift mutations of TRESK, a two-pore-domain K+ channel, lead to the production of a second protein fragment, which carries the pathophysiological function by inhibiting TREK1 and 2, due to a mechanism called frameshift mutation-induced alternative translation initiation (fsATI).
INTRODUCTION
Migraine is a common, disabling neurological disorder with a genetic, environmental, and hormonal component with an annual prevalence estimated at $15%. It is characterized by attacks of severe, usually unilateral, and throbbing headache and can be accompanied by nausea, vomiting, and photophobia. Migraine is clinically divided into two main subtypes: migraine with aura (MA), when a migraine is preceded by transient neurological disturbances that are usually visual, and migraine without aura (MO). Cortical spreading depression (CSD) underlies the aura, although its precise relationship to headache is unclear. Activation and sensitization of trigeminal neurons (TG) leading to the release of pro-inflammatory peptides is likely a key component in pain initiation and transmission in migraine (Noseda and Burstein, 2013; Yan and Dussor, 2014) .
Recent evidence points to a pivotal contribution of a variety of two-pore-domain potassium (K2P) channels in chronic pain processing. The diverse K 2P channel family is made of 15 subtypes, which form 6 subfamilies. The activity of these channels drives the membrane potential toward the K + equilibrium potential and therefore reduces cellular excitability. Expression of several K 2P channel subunits has been detected in nociceptive dorsal root ganglion and trigeminal neurons (Alloui et al., 2006; Bautista et al., 2008; Blin et al., 2016; Morenilla-Palao et al., 2014; No€ el et al., 2009; Yamamoto et al., 2009) . One subtype of K 2P channels that is highly expressed in sensory neurons, TRESK, has been directly linked to MA via a causally linked 2-bp frameshift mutation (F139WfsX24) identified in the KCNK18 gene, which causes premature truncation of TRESK (''TRESK-MT''; Lafreniè re et al., 2010; Wood, 2010) . This mutation segregated perfectly with the MA phenotype in a large pedigree and was shown to produce a non-functional protein that can serve as a dominant negative that functionally downregulates the wildtype (WT) TRESK channel (Lafreniè re et al., 2010; Wood, 2010) . TRESK-MT has been shown to induce hyperexcitability of TG neurons (Guo et al., 2014; Liu et al., 2013) , which likely underscores its role in migraine. However, in subsequent genetic screening studies, another missense TRESK variant, C110R, was identified (Andres-Enguix et al., 2012) . TRESK-C110R, similar to TRESK-MT, exerts a dominant-negative effect on WT-TRESK in heterologous cells, but expression of this mutant was found to have no effect on TG excitability (Guo et al., 2014) . This absence of effect explains why this mutant was found in both migraine patients and control subjects (Guo et al., 2014) . Therefore, despite the fact that both mutations lead to the same apparent effect on TRESK function, only TRESK-MT is able to increase TG excitability and is linked to migraine pathophysiology.
Classically a eukaryotic mRNA is thought to contain one translation start codon, which allows the production of a single protein species. However, in some cases, eukaryotic ribosomes can recognize several alternative translation start sites to induce the formation of several different proteins from the same mRNA (Kochetov, 2008) . This alternative translation initiation is a means of expanding the proteome (Kochetov, 2008) and has been shown to increase the functional diversity of K 2P channels (Thomas et al., 2008) , raising the possibility that it plays a role in TRESK-mediated migraine pathophysiology.
In this study, we addressed why TRESK-MT (F139WfsX24), but not TRESK-C110R, is able to increase TG excitability and, potentially, play a role in migraines. Using single-molecule fluorescence and chemical optogenetic methods, we found that TRESK is able to heterodimerize with 2 distantly related K 2P channels from another subfamily, TREK1 and TREK2, and that TRESK-MT strongly inhibits TRESK, TREK1, and TREK2 currents. In stark contrast, we show that TRESK-C110R is only able to inhibit TRESK, but not TREK1 or TREK2. Furthermore, we show, using double knockout (KO) mice for TREK1 and TREK2, that TRESK-MT increases TG neuronal excitability by inhibiting TREK1 and TREK2. Consistent with a role for TREK1 and TREK2 in migraine induction, we found that double-KO mice for TREK1 and TREK2 present, at rest, a migraine-like allodynia phenotype. These results resolve the contradictory lack of effect of TRESK-C110R, which targets only TRESK and not TREK1 or TREK2. Strikingly, we next find that the 2-bp frameshift mutation of TRESK-MT puts an alternative start codon in frame, which leads to the translation of a second TRESK fragment, termed MT2, which specifically co-assembles with TREK1 and TREK2 to downregulate their function, leading to the TG excitability increase. Consistent with a role for MT2 in migraine induction, we found that MT2 expression within the trigeminal ganglia induced a migraine-like allodynia phenotype in rat. Finally, we find that other previously uncharacterized migraine-associated TRESK mutations also produce multiple fragments via alternative translation initiation (ATI) that can have distinct effects on TRESK and TREK channels. Together, these findings identify frameshift-induced ATI (fsATI) as a mechanism initiated by TRESK mutations, which leads to two protein fragments with dominant-negative effects on distinct channel targets to, ultimately, increase sensory neuron excitability, which may contribute to migraine induction.
RESULTS

TRESK Heteromerizes with TREK1 and TREK2
Despite the fact that K 2P channels share a similar architecture and global function, they share a low level of sequence identity, even between members of the same subfamily. Surprisingly, this low level of identity does not preclude heteromerization, as we and others recently showed within the TREK subfamily Hwang et al., 2014; Lengyel et al., 2016; Levitz et al., 2016) . Based on this and the fact that TG neurons express many K 2P channels (TREK1, TREK2, TRAAK, TASK1, and TASK3; Bautista et al., 2008; Yamamoto et al., 2009) , we hypothesized that the difference between TRESK mutants is due to their differential ability to modify the function of other K 2P chan-nels through heteromerization. To assess the ability of TRESK to heteromerize with other K 2P channels that are expressed in TG neurons, we used the single-molecule pull-down (''SiMPull'') assay (Jain et al., 2012) to visualize individual antibody-immobilized protein complexes on polyethylene-glycol-passivated glass coverslips ( Figure 1A) . We co-expressed GFP-TRESK with either hemagglutinin HA-TRESK, HA-TREK1, HA-TREK2, HA-TRAAK, HA-TASK1, or HA-TASK3 and assessed their ability to co-immunoprecipitate (coIP) GFP-TRESK via an anti-HA antibody. HA-TRESK, HA-TREK1, and HA-TREK2, were able to coIP many fluorescent GFP-TRESK spots ( Figures 1B and 1C) , whereas no GFP-TRESK spots were observed for HA-TRAAK, HA-TASK1, or HA-TASK3 ( Figure 1C ), indicating that TRESK co-assembly with other K 2P channels is specific for TREK1 and TREK2. Importantly, controls showed that identical results were observed in two different non-ionic detergents ( Figure 1C ), that similar expression levels were seen for GFP-TRESK when co-expressed with HA-TREK1 or HA-TRESK ( Figure S1A ), that all HA-tagged K2P constructs were able to pull down themselves (Figures S1B and S1C), and that pull-down was dependent on the presence of the anti-HA antibody ( Figure S1D ) and confirm that TREK1, TREK2, and TRESK can be co-expressed in the same cultured TG neurons using immunofluochemistry and single-cell RT-PCR ( Figure S1F ).
We next used photobleaching step analysis (Ulbrich and Isacoff, 2007) to determine the stoichiometry of TREK1 and TRESK complexes to test the hypothesis that they form heterodimers. First, we confirmed that HA-GFP-TREK1 form homodimers in our assay by observing $70% 2-step bleaching for each when expressed and immunoprecipitated alone with anti-HA antibodies ( Figure S2A ), consistent with the formation of strict dimers with a GFP maturation rate of $80%. Then, we counted the number of GFP-TRESK subunits within a HA-TREK1/GFP-TRESK complex by observing bleaching steps of GFP-TRESK coIP with immobilized HA-TREK1 ( Figure S2C ). The majority of fluorescence intensity trajectories showed one bleaching step ($70%; Figure S2C ). This distribution is similar to the one observed for HA-TREK1/GFP-TREK1 complexes ( Figure S2B ) and agrees well with a 1:1 stoichiometry showing that TREK1-TRESK is primarily a heterodimer.
To test the functionality of the TREK1-TRESK heterodimer, we developed a heterodimerization assay based on an engineered ''photoswitchable conditional subunit'' (TREK1-PCS) of TREK1. The TREK1-PCS is a TREK1 subunit where the C terminus has been deleted to produce endoplasmic reticulum retention, which can be rescued through co-assembly with a full-length subunit (Sandoz et al., 2012) . Following co-assembly and surface targeting, TREK1-PCS can then optically control the channel via a tethered photoswitchable blocker (''MAQ''), which attaches to a genetically engineered cysteine. Therefore, gain of photosensitivity of an identified co-expressed TREK-interacting subunit allows for the verification of a functional heteromer with TREK1. As expected, expression of TREK1-PCS alone did not generate a photoswitchable current ( Figure 1D ), but co-expression with either TREK1 or TRESK induced a robust photoswitchable current ( Figures 1E and 1F) , indicating that the TRESK subunit is able to co-assemble with TREK1-PCS. Consistent with SiMPull data, no photocurrent was observed when TASK1 ( Figure 1G) or TASK3 ( Figure S1E ) were co-expressed with TREK1-PCS. Furthermore, the bleaching step distribution of GFP-TREK1-PCS spots coIPed with immobilized HA-TREK1 is similar to HA-TREK1/GFP-TREK1; the majority of fluorescence spots showed one bleaching step ($70%; Figure S2D ), supporting the conclusion that the light-gated TREK1-PCS/TRESK current is carried by a TREK1-PCS/TRESK heterodimer with a common pore.
Next, to test the functional properties of the TREK1-TRESK heteromer, we constructed a linked, tandem dimer to have a uniform representation at the surface of the cell of the TREK1-TRESK heteromer ( Figure S3 ). This heteromeric channel displayed properties that are a mix of those from TREK1 and TRESK homodimers. Notably, TRESK is insensitive to arachidonic acid and TREK1 is sensitive ( Figures S3A-S3C ) and TRESK-TREK1 tandems show an intermediate sensitivity to arachidonic acid ( Figure S3C ). Furthermore, similar to TRESK, but not TREK1, TRESK-TREK1 tandems showed sensitivity to intracellular calcium, as tested with ionomycin application (Figures S3D and S3F) . Consistent with this, the light-gated TREK1-PCS/TRESK current is also calcium sensitive ( Figures S3E and S3F ), confirming that the light-gated TREK1-PCS/TRESK current is carried by a TRESK1-TRESK heteromer with a common pore.
Having found that TREK can physically and functionally heteromerize with TRESK and that all three channel subtypes are co-expressed in sensory neurons, we next investigated the ability of TRESK mutants to modify TREK1 and TREK2 currents.
TRESK-MT, but Not TRESK-C110R, Acts as a Dominant
Negative on TREK1 and TREK2 Channels As previously shown (Andres-Enguix et al., 2012) , both TRESK-MT and TRESK-C110R exert a dominant-negative effect on whole-cell TRESK currents (Figures 2A-2C ). Because TREK1 can co-assemble with TRESK ( Figure 1) , we addressed the impact of the MT and C110R variants on TREK1 current. We found that TRESK-C110R co-expression did not modify TREK1 current, whereas TRESK-MT co-expression induced a nearcomplete inhibition of TREK1 current ( Figures 2D-2F ). Similar to TREK1, TRESK-MT, but not TRESK-C110R, strongly inhibited TREK2 current ( Figures 2G-2I ). This dominant-negative effect is specific and likely dependent on co-assembly because TASK1, TASK3, and TRAAK, which do not coIP with TRESK (Figure 1 ), were not sensitive to TRESK-MT co-expression ( Figure S4 ). To address why TRESK-C110R does not modify TREK1 or TREK2 current, we used the SiMPull assay to test the ability of TRESK-C110R to physically interact with TREK1. We co-expressed HA-TREK1 with either GFP-TRESK or GFP-TRESK-C110R and tested their ability to be coIPeded with HA-TREK1 via an anti-HA antibody. Whereas GFP-TRESK was able to be coIPed with HA-TREK1, leading to many fluorescent spots, (D-G) Co-expression of TREK1-PCS with WT-TREK1 produces a heteromeric channel that traffics from the endoplasmic reticulum (ER) to the plasma membrane (PM) and which can be light gated due to attachment of a photoswitchable blocker to the TREK1-PCS. TREK1-PCS expression alone does not produce any photoswitchable current (D), but co-expression of TREK1 (E) or TRESK (F), but not TASK1 (G), leads to a photoswitchable current indicating that TREK1-TRESK form functional heteromers, but there is no functional assembly of TREK1 and TASK1. See also Figures S1, S2, and S3. very few spots were observed for GFP-TRESK-C110R (Figure S5A) . This indicates that TREK1 can co-assemble with TRESK and that the C110R mutation leads to a drastic reduction of this association, explaining why TRESK-C110R has no effect on TREK1 current. Together, these data show that TRESK-MT can inhibit TRESK, TREK1, and TREK2, whereas TRESK-C110R is only able to inhibit TRESK. Based on the fact that TRESK-MT, but not TRESK-C110R, is able to induce TG neuron hyperexcitability (Guo et al., 2014; Liu et al., 2013) , we hypothesized that TRESK-MT induces sensory neuron hyperexcitability primarily by acting on TREK1 and TREK2, not TRESK.
TRESK-MT Increases Neuronal Excitability through the Inhibition of TREK1 and TREK2
To investigate the role of TREK1 and TREK2 in the induction of TG hyperexcitability by TRESK-MT, we tested whether overexpression of GFP-TRESK-MT alters the passive and active electrophysiological properties of small-diameter (<25 mm) TG neurons from wild-type or TREK1/TREK2 double-knockout (TREK1 À/À / TREK2 À/À ) mice. As previously shown, TRESK-MT expression in WT TG neurons led to a decrease of the lamotrigine current ( Figure S6 ), leading to an increase in excitability ( Figure 3C ), which included a decrease in the rheobase (74 ± 11 pA versus 47 ± 5 pA; p < 0.05 for TG neurons expressing GFP or TRESK-MT, respectively) and an increase in the number of action potentials (APs) evoked by suprathreshold current injections compared to control (Figures 3A and 3C) . As shown in Figure 3B , neurons from TREK1 À/À /TREK2 À/À mice were more excitable than WT TG neurons. These neurons have a smaller lamotrigine current ( Figure S6 ), smaller rheobase (55 ± 6 pA; p < 0.05) and a significant increase in the number of APs evoked by suprathreshold current injections compared to WT TG neurons. Consistent with a role for TREK1 and 2 in mediating the effects of TRESK-MT, TRESK-MT overexpression did not alter the excitability of TREK1 À/À /TREK2 À/À mice ( Figure 3D ). TREK1 À/À /TREK2 À/À TG neurons showed no increase in the number of evoked APs or a reduction in rheobase (55 ± 6 pA versus 53 ± 5 pA for TG neuron expressing GFP or TRESK-MT, respectively; p > 0.5). Together, these data strongly support a major role for TREK1 and TREK2 in the control of TG neuron excitability and support the idea that TRESK-MT differs functionally from TRESK-C110R in its ability to target TREK1 and TREK2 to increase the excitability of TG neurons, which is likely a crucial step in the induction of migraines.
TREK1 -/-/TREK2 -/-Mice Show a Mechanical Allodynia, which Is Not Increased by NO Donors
Having found that expression of the TRESK-MT mutant increases TG excitability through TREK1-TREK2 inhibition, we hypothesized that TREK1 À/À /TREK2 À/À mice would show an increased susceptibility to a migraine-related phenotype. Migraine is associated with an increase of the sensitivity to all sensory modalities, and cutaneous allodynia can be used as a quantifiable marker of migraine disorder (Bates et al., 2010; Verkest et al., 2018) . One approach to model acute and chronic migraine is the quantification of this increase in response to known migraine triggers, such as nitric oxide (NO) donors (Bates et al., 2010) , including isosorbide dinitrate (ISDN) (Verkest et al., 2018) . We quantified ISDN-evoked mechanical allodynia in TREK1 À/À /TREK2 À/À and wild-type controls in acute and chronic conditions. In a first experiment, paw mechanical nociception thresholds were determined with a dynamic von Frey aesthesiometer before and during a 3-hr period after intraperitoneal injection of ISDN (10 mg/kg; Figure 3E ; Bates et al., 2010; Verkest et al., 2018) . In a second experiment, we assessed mechanical nociception thresholds in both TREK1 À/À /TREK2 À/À and wild-type controls by intraperitoneally injecting ISDN every day for four days as a model of chronic migraine-associated pain ( Figure 3E ). We found that, at rest, TREK1 À/À /TREK2 À/À mice showed a decreased mechanical threshold compared to WT mice (2.6 ± 0.1 g versus 3.9 ± 0.1 g; p < 0.001). Notably, the basal mechanical threshold of (A-D) TREK1 À/À /TREK2 À/À TG neurons are more excitable than WT TG neurons and are not sensitive to TRESK-MT overexpression. (A) Representative traces of action potentials (spikes) generated by incremental depolarizing current injections in small-diameter TG neurons. (B) Input-output plots of spike frequency in response to 1-s depolarizing current injection in untransfected, small TG neurons from WT and TREK1 À/À /TREK2 À/À double-KO mice. (C and D) TRESK-MT acts as a dominant negative on TREK1 and TREK2 channels to increase excitability of TG neurons. Input-output plots of the spike frequency in response to 1-s depolarizing current injection in transfected small TG neurons from WT (C) and TREK1 À/À /TREK2 À/À double-KO mice (D) show that an increase in excitability elicited by TRESK-MT is observed in WT, but not T1 À/À /T2 À/À , neurons. The numbers of tested cells are indicated in parentheses on the plots and come from at least 4 different animals. Student's t test (*p < 0.05; **p < 0.01; ***p < 0.001).
(E-H) TREK1 À/À /TREK2 À/À double-knockout animals present a migraine-like hypersensitivity to mechanical stimuli. (E) Schematic of experimental behavioral paradigms. Green arrows represent the injection of ISDN, a known migraine trigger. Blue arrows represent the measurement of mechanical sensitivity. (F) Paw withdrawal mechanical threshold, assessed after the first ISDN injection, were significantly decreased in double-knockout animals and remained less than WT for the first 1.5 hr following ISDN injection. (G) Mechanical responses, assessed prior to and after chronic ISDN injections, were significantly decreased in double-knockout animals. (H) Variation (DThreshold (g)) of the paw withdrawal mechanical threshold induced by ISDN chronic treatment or by topiramate injection. Mechanical responses were assessed before and after ISDN chronic (4 days) treatment (left bars) and before and 2 hr after topiramate injection (right bars) in WT and TREK1 À/À /TREK2 À/À double-knockout ISDN-nontreated mice. Numbers of mice tested are indicated in parentheses on the plots; Student's t test to compare WT versus TREK1 À/À /TREK2 À/À mice (*p < 0.05; **p < 0.01; ***p < 0.001). Data are represented as mean ± SEM. See also Figure S6 . TREK1 À/À /TREK2 À/À mice is similar to the allodynic threshold observed 1.5 hr after acute ISDN injection in WT mice ( Figure 3F ; p = 0.831). In the acute model experiment, the injection of ISDN in TREK1 À/À /TREK2 À/À mice does not induce any modification of the mechanical threshold, which remained significantly lower than in wild-type controls during the first 1.5 hr following ISDN injection ( Figure 3F ; p < 0.001 after 30 min and p < 0.01 after 1 hr with a linear mixed-effects model).
In the chronic migraine-associated pain assay, the mechanical thresholds remained significantly lower for TREK1 À/À / TREK2 À/À mice compared to wild-type controls, but the difference was strongly reduced (Dmechanical threshold induced by 4 days ISDN treatment 0.33 ± 0.2 g in TREK1 À/À /TREK2 À/À versus 1.12 ± 0.1 g in WT mice; Figure 3G ).
Having found that TREK1 À/À /TREK2 À/À mice show basal mechanical allodynia that cannot be further increased by an ISDN injection, we wondered whether a treatment used in prophylaxis in migraine patient, topiramate, could reverse this observed migraine-like phenotype as was observed in models of nitroglycerin (NO) donor-induced migraine (Pradhan et al., 2014) and in a model of ISDN-induced migraine in rats (Verkest et al., 2018) . We assessed the mechanical nociception threshold in TREK1 À/À / TREK2 À/À mice before and 2 hr following the intraperitoneal injection of 30 mg/kg of topiramate. Treatment with topiramate reversed partially the chronic basal allodynia seen in TREK1 À/À / TREK2 À/À mice (Dmechanical threshold of 1.2 ± 0.2 g; Figure 3H ), as was previously observed for a nitroglycerin-evoked form of al- lodynia (Pradhan et al., 2014) . As a control, we tested non-treated ISDN WT mice and did not observe any significant shift of the mechanical threshold following topiramate treatment ( Figure 3H ).
These data demonstrate that, at rest, the TREK1 À/À /TREK2 À/À mice present an allodynia phenotype, which is similar to the phenotype observed in ISDN-treated WT animals. This is consistent with a role of TREK1/TREK2 in trigeminal sensory neuron hypersensitivity that is relevant to migraine, which is also supported by the reversion induced by topiramate, a drug used in the clinic to treat chronic migraine.
TRESK-MT Mutation Induces the Translation of a Second Protein, MT2
We next explored how TRESK-MT exerts its effects on TREK channels at the molecular level. The F139WfsX24 frameshift mutation of TRESK-MT results in the premature truncation of the human TRESK protein from 384 amino acids (aas) to 162 aas. The truncated TRESK includes the first 138 aas of wild-type TRESK followed by a 24-aa aberrant sequence. The corresponding mutation has very similar effects on the mouse TRESK gene, generating a truncated protein with the first 149 aas of wildtype TRESK and followed by a 50-aa aberrant sequence at the C terminus ( Figure 4B ). We fused a GFP tag to the N terminus of the mouse TRESK-MT and tested its ability to be immobilized by HA-TRESK, HA-TREK1, or HA-TREK2 in the SiMPull assay. Surprisingly, only HA-TRESK was able to coIP GFP-TRESK-MT via an anti-HA antibody ( Figure 4A ). This result confirms that TRESK-MT associates with TRESK to induce its dominant-negative effect but raises the question of how TRESK-MT is able to inhibit TREK1 and TREK2 without direct association.
It has been hypothesized that ATI of eukaryotic mRNAs, including those that encode K 2P channels (Thomas et al., 2008) , may provide a method to expand the proteome (Kochetov, 2008) . A close examination of the nucleotide sequence of TRESK-MT revealed that the F139WfsX24 frameshift mutation places two new ATG codons in frame with the reference open reading frame of TRESK (ATGs at position +356 and +407 for the human TRESK cDNA and +389 and +490 for the mouse cDNA). We hypothesized that one of these codons may serve as an ATI site that can lead to the formation of a second truncated TRESK protein, termed ''MT2,'' that would include a short (either 2 or 19 aas) N-terminal aberrant sequence followed by the C-terminal part of TM2, including the 2-3 intracellular loop, TM3, P2 loop, TM4, and the C-terminal domains ( Figure 4B ). To test whether MT2 is co-translated with MT1, we introduced an N-terminal mCherry tag in frame with MT1 and a C-terminal GFP in frame with MT2 within the mouse TRESK-MT cDNA (''mCherry-TRESK-MT-GFP''). Expression of this construct led to HEK293T cells with both mCherry and GFP fluorescence, showing the co-translation of mCherry-MT1 and MT2-GFP (Figure 4C ). This co-translation was observed in other cell lines, including MDCK cells ( Figure 4C ), as well as in primary TG neurons ( Figure 4C ). Next, we introduced an N-terminal HA tag in frame with MT1 and another one in frame with MT2 within the mouse TRESK-MT cDNA (''HA-TRESK-MT-HA''). Lysate from cells transfected with HA-TRESK-MT-HA was probed in a western blot with anti-HA antibodies, and 2 bands, with a similar intensity, corresponding to the expected molecular weights for MT1 ($23 kDa) and MT2 ($29 kDa) were detected ( Figure 4D ). Together, these data clearly show that TRESK-MT leads to the production of two distinct fragments of TRESK.
To probe the function of MT2, we introduced a stop codon into the MT2 open reading frame (ORF) of TRESK-MT at the beginning of the 2-3 loop ( Figure 4B ), inducing the loss of expression of MT2 ( Figure S7A ). As shown in Figure 5 , whereas the introduction of the stop codon in the MT2 ORF did not change the ability of TRESK-MT to inhibit TRESK current ( Figure 5B ), this stop codon abolished the ability of TRESK-MT to produce a dominant-negative functional effect on TREK1 ( Figure 5A ). We next confirmed the importance of this second ORF by mutating, in TRESK-MT, the putative ATI start codons one by one. Mutation of the first ATG abolished the ability of TRESK-MT to inhibit TREK1 ( Figure 5C ), but not TRESK ( Figure 5D ), whereas mutation of the second ATG did not alter the ability of TRESK-MT to inhibit TREK1 current ( Figures 5C and S7B) . These data indicate that the ATI site is the first internal ATG. As a control, we mutated a third ATG, which is also present in the WT-TRESK sequence, and found that it did not change the ability of TRESK-MT to inhibit both TRESK and TREK1 currents ( Figures 5C and S7C ). Similar to TREK1, introduction of a stop codon into the MT2 ORF or mutation of the first ATG also abolished the inhibition of TREK2 by TRESK-MT ( Figures 5E and 5F ). To further demonstrate that the first ATG serves as a start codon, we mutated the potential Kozak sequence GCTATGG to CCTATGC and found that alteration of the Kozak sequence strongly reduced the inhibitory effect of TRESK-MT on TREK1 current ( Figures 5C and S7D ) without affecting the effect on TRESK (Figures 5D and S7E).
MT2, but Not MT1, by Acting as a Dominant Negative on TREK1 and TREK2 Channels, Increases Neuronal Excitability of WT Small TG Neurons, Leading to Facial Allodynia To independently express MT1 and MT2 for functional characterization, we sub-cloned both ORFs into separate mammalian expression vectors. Co-expression of MT2 with TRESK did not modify TRESK current ( Figures 6B and 6E) , and MT1 co-expression induced a $3-fold decrease of the current, which was similar to what was observed for the co-expression of the full TRESK-MT construct (Figures 6A and 6E) . On the contrary, coexpression of MT1 did not modify TREK1 current ( Figures 6C  and 6E ), but co-expression of MT2 induced a $4-fold decrease of the current, similar to what was observed with co-expression of the full TRESK-MT construct (Figures 6D and 6E) . Similar results were obtained for TREK2 ( Figures 6E and S8) . Consistent with the functional data, we found that GFP-MT2 is coIPed with HA-TREK1 or HA-TREK2 in the SiMPull assay ( Figure 6F) .
To validate the physiological role of interaction between TREK1, TREK2, and MT2, we tested the functional effect of MT2 in TG neurons. Whereas MT1 expression did not alter the excitability of WT TG neurons ( Figures 7A and 7B ), MT2
increased it significantly ( Figures 7A and 7C ). In fact, MT1 did not modify the rheobase (74 ± 11 pA versus 79 ± 5 pA; p > 0.5 for TG neurons expressing GFP or MT1, respectively) and did not modify the number of APs evoked by suprathreshold current injections compared to control. Conversely, MT2 expression in WT TG neurons led to an increase in excitability (Figure 7) , which included a decrease in the rheobase (74 ± 11 pA versus 55 ± 5 pA; p < 0.05 for TG neurons expressing GFP or MT2, respectively; p < 0.05) and an increase in the number of APs evoked by suprathreshold current injections compared to control (Figures 7A and 7C ). We confirmed that this effect is linked to TREK1 and TREK2 because MT2 overexpression failed to increase the excitability of TREK1 À/À /TREK2 À/À TG neurons ( Figure 7D ).
Having found that MT2, by inhibiting TREK1 and TREK2, is sufficient to increase TG excitability, we asked whether MT2 expression in TG ganglia would induce a migraine-related phenotype. We conducted behavioral experiments in rats in which MT2 was virally overexpressed within the trigeminal ganglia. Rats allowed to test the mechanical pain threshold on the face, which is directly linked to TG excitability, constituting a relatively direct, reliable, and quantifiable marker of migraine disorder in clinical contexts as well as in NO-induced migraine (Pradhan et al., 2014; Kopruszinski et al., 2017; Harris et al., 2017) . As shown in Figure 7F , MT2 expression in TG ganglia (Figure S9 ) significantly increased the facial mechanical threshold (3.3 ± 0.4 g versus 7.7 ± 0.4 g; p < 0.001). Furthermore, as was seen for the TREK1 À/À /TREK2 À/À mice, the basal mechanical facial threshold of MT2-expressing rats is similar to the threshold observed 1.5, 2, and 3 hr after acute ISDN injection in WT rats. Having found that MT2 overexpression induced allodynia, we quantified ISDN-evoked mechanical allodynia and found that MT2 overexpression in TG neurons prevents any further effect of ISDN on facial allodynia. This loss of effect of NO donors may be due to the fact that the ''ceiling'' level of allodynia has already been reached.
Together, these data demonstrate that, at rest, the overexpression of MT2 leads to an increase in TG excitability and a chronical cutaneous allodynia to a similar level to what is observed following NO-donor injection. This is also similar to the allodynia observed in TREK1 À/À /TREK2 À/À double-KO mice (Figure 3 ).
MT2-Producing Alternative Translation Initiation Is Found in Other Migraine-Associated TRESK Mutants
Having found that MT2 is responsible for the migraine-associated increase in TG excitability and induction of a migraine-like phenotype through the inhibition of TREK1 and TREK2, we anticipated that other frameshift mutations may exist that place the ATG at position +356 in frame with the reference open reading frame of TRESK. Such mutations would lead to the formation of MT2. This mutation could be either a 2-bp deletion or 1-bp insertion in the region between the ATG at position +356 and the ATG at position +427 ( Figure S10 ). We used the Exome Aggregation Consortium (ExAC) database (Lek et al., 2016) and found one variant (Y121LfsX44) with a T duplication (+1 pb; c.361dupT) that places the ATI site in frame with the TRESK ORF ( Figure S9 ). We introduced this insertion into the mCherry-TRESK-GFP (mCherry-TRESK-c.361dubT-GFP) sequence and found, similar to mCherry-TRESK-MT-GFP ( Figure 4C ), that this construct led to HEK293T cells with both mCherry and GFP fluorescence ( Figure 8A ) due to the co-translation of both MT1 and MT2 proteins. Similar to TRESK-MT, this mutant is able to inhibit TRESK, TREK1, and TREK2 ( Figure 8 ). As was seen for TRESK-MT ( Figure 5 ), introduction of a stop codon into the MT2 ORF (TRESK c.361dupT STOP ) of this mutant abolished its ability to inhibit TREK1 and TREK2 (Figure 8 ), but not TRESK. Because this Y121LfsX44 mutation leads to the same molecular effects as TRESK-MT on TREK function, we hypothesized that it may be associated with a migraine phenotype. To address this, we looked in the ClinVar database (Landrum et al., 2016) and found that this mutant has been correlated with a migraine phenotype (RCV000490385.1).
DISCUSSION
Although initial findings of migraine-associated mutations of TRESK represented a major breakthrough (Lafreniè re et al., 2010), a direct relationship between TRESK channel disruption and migraine has been challenged based on the discovery of a TRESK mutation (C110R) that produces a dominant-negative form of TRESK but is found in a control cohort population (Andres-Enguix et al., 2012) . The presence of this mutation in control individuals indicates that a single non-functional TRESK variant alone may not be sufficient to cause migraines, consistent with the genetic complexity of this disorder. In this study, we have addressed this controversy and found that the migraine-associated (B and C) Input-output plots of spike frequency in response to 1-s depolarizing current injections in WT small-diameter TG neurons transfected with either GFP (''WT''), the GFP-tagged MT1 subunit (''MT1''; B), or the GFP-tagged MT2 subunit (''MT2''; C). (D) Input-output plots of spike frequency show a lack of effect of GFP-MT2 expression on TG neurons from TREK1/TREK2 double-KO mice (T1 À/À /T2 À/À ). (E-G) MT2 overexpression in TG leads to facial mechanical allodynia in rats. (E) Schematic of experimental behavioral paradigms. After a week of habituation, rats were injected with 10 mL of AAV2 encoding for either MT2 + GFP or GFP. (F) Face withdrawal mechanical threshold assessed after trigeminal virus infection encoding either GFP (WT rat condition) or MT2. (G) Face withdrawal mechanical threshold, assessed after the first ISDN injection. The threshold for MT2-expressing rats was significantly decreased before the injection and remained less than WT for the first 1.5 hr following ISDN injection. The numbers of tested cells and rats are indicated in parentheses on the plots. Mice neurons come from at least 5 different animals. Student's t test (*p < 0.05, **p < 0.01, and ***p < 0.001). Data are represented as mean ± SEM. See also Figure S9 . mutation of TRESK exerts its effects on sensory neurons by associating and serving as a dominant negative not only for TRESK but also for TREK1 and TREK2 channels. In stark contrast, TRESK-C110R is not able to regulate TREK channels. Consistent with a function of TREK1 and TREK2 in TRESK-MTinduced migraine, the TREK1 À/À /TREK2 À/À mice show a migraine-like hypersensitivity to mechanical stimuli. Surprisingly, we find that migraine-associated frameshift mutations of TRESK induce alternative translation initiation that allows the formation of a second product, MT2, which mediates the dominant-negative action on TREK1 and TREK2 when overexpressed. This dominant-negative action on TREK1 and TREK2, ultimately, leads to an increase in TG neuron excitability and a migrainelike hypersensitivity to facial mechanical stimuli. Supporting this phenomenon as a general mechanism, we found another migraine-associated frameshift mutation in TRESK that produces a similar ORF shift, which also leads to the formation of MT2. Together, these findings support a role of fsATI and for TREK potassium channels as a key part of sensory neuron excitability and the underlying cellular mechanism of migraine.
We and others Hwang et al., 2014; Lengyel et al., 2016; Levitz et al., 2016) have recently shown that K 2P channels are able to form both homodimeric and heterodimeric potassium channels. In this study, we show that TREK and TRESK readily assemble as heteromers. To co-assemble natively, TRESK and TREK must be expressed in the same cells. We and others have found that TG neurons from mice can co-express TREK1, TREK2, and TRESK (Bautista et al., 2008) , and it has been confirmed that TREK1 and TRESK are also co-expressed in human TG neurons (Flegel et al., 2015) . Recent single-cell RNA sequencing data on dorsal root ganglion (DRG) sensory neurons from mice have also shown that co-expression of TRESK with TREK-2 and/or TREK-1 occurs in some subtypes of sensory neurons involved in pain signaling, including peptidergic and non-peptidergic subtypes (Usoskin et al., 2015; Zeisel et al., 2018) . Single-channel recordings also identified these channels in medium-and small-sized sensory neurons of the DRG, which are likely involved in nociception (Kang et al., 2005) . In this study, we have supported these previous findings by using immunohistochemistry and single-cell RT-PCR (Figure S1) , as well as pharmacology ( Figure S6) , to confirm the co-expression of TRESK and TREK channels in sensory neurons. Nevertheless, the relative expression levels of TREK and TRESK in TG neurons are, as is the case for the DRG, likely variable, and therefore, we expect a differential population of homo and heteromers from cell to cell. Expression studies with singlecell precision are ultimately needed to precisely determine which subpopulations co-express different relative amounts of each channel. We show that this TRESK-TREK heteromer is a functional dimer because one TRESK is able to co-assemble with one TREK subunit to form a heterodimeric channel with a common pore using a photoswitchable conditional TREK1 (Sandoz et al., 2012) . This is quite surprising given that TREK1/2 and TRESK are in different K 2P channel subfamilies and only show low sequence identity of $19.7% (Sano et al., 2003) . We previously found that all members of the TREK channel subfamily (TREK1, TREK2, and TRAAK) can co-assemble but that TREK was unable to interact with TASK channels. Similar to the other reported heteromers, TREK1-TRESK heterodimers show unique biophysical behavior that blends the properties of the parent subunits. Notably, TREK1-TRESK is both arachidonic-acidand calcium-sensitive. In this study, we also show that TRESK does not heteromerize with three other K 2P channels, one from the TREK subfamily, TRAAK, and two from the TASK subfamily, TASK1 and TASK3. Together, this indicates that not all pairs of K 2P channel subunits are able to interact and that there are indeed rules of interaction that remain to be deciphered. Future work will be needed to determine the molecular mechanisms and structural interfaces that mediate specific K 2P heteromer assembly and the associated functional consequences of heteromerization.
TRESK channels are expressed in the DRG and show their highest expression levels in TG. In DRG and TG, TRESK is most abundant in the small-and medium-size sensory neurons (Dobler et al., 2007; Lafreniè re et al., 2010) . In TG neurons, introduction of TRESK-MT has been shown to reduce the lamotrigine-sensitive K + current, leading to an increase in excitability (Guo et al., 2014; Liu et al., 2013) . This increase of TG excitability cannot be explained by TRESK inhibition because TRESK-C110R, which also strongly inhibits wild-type TRESK, does not inhibit the lamotrigine-sensitive K + current and does not increase TG excitability, explaining its lack of involvement in migraine (Guo et al., 2014) . TREK1 and TREK2 are also expressed in DRG and show high expression levels in TG Yamamoto et al., 2009 ). Furthermore, TREK1 and TREK2 have recently been shown to also be lamotrigine sensi-tive (Walsh et al., 2016;  Figure S6 ). We found that TRESK-MT inhibits TREK1 and TREK2 to increase TG excitability, showing that TREK1 and TREK2 control TG neuron excitability. To address the impact of this sensory neuron excitability increase, linked to TREK1 and TREK2 inhibition, we tested TREK1 À/À / TREK2 À/À mice for their susceptibility to a migraine-like phenotype. Migraine is associated with increased sensitivity to all sensory modalities, and it appears that cutaneous allodynia can be used as a quantifiable marker of migraine disorder (Bates et al., 2010) . Increase of basal mechanical hyperalgesia induced by TREK1 and TREK2 invalidation, to a similar level compared to WT animals after ISDN injection, is in agreement with a KO-induced increase of sensory neuron excitability that is relevant to migraine (Brennan et al., 2013) . Furthermore, trigeminal overexpression of MT2 in rats also induced a chronic facial allodynia. This facial allodynia can be a facial hypersensitivity without migraine; however, orbitofacial allodynia is clearly accepted as a reflection of the activity of TG neurons and therefore relevant to migraine (Pradhan et al., 2014; Kopruszinski et al., 2017; Harris et al., 2017) . Nevertheless, inhibition of TREK1/TREK2 by TRESK-MT2 fragments will depend on its physiological expression and remains to be demonstrated without overexpression. Topiramate was previously shown to inhibit NO-donor-induced acute or basal chronic allodynia (Pradhan et al., 2014) . We found that topiramate was able to partially reverse TREK1-TREK2 invalidation-induced allodynia, which is consistent with its action as a prophylactic migraine therapy (Pradhan et al., 2014) . Therefore, these results seem to indicate that the dysfunction of TREK1 and TREK2, and not of TRESK alone, contributes to the increase of TG excitability, which may lead to an alteration of pain processing like during migraine, suggesting that TREK1, TREK2, and TREK-TRESK heterodimers should be considered as new targets for migraine treatment.
An important remaining question is: how can TREK1 and TREK2 dysfunction lead to migraine phenotypes? Importantly, the TRESK-MT mutant has been found in migraine with aura phenotype (Lafreniè re et al., 2010) . Aura has been linked to CSD, which precedes the activation of TG neurons (Noseda and Burstein, 2013) . TREK1 and TREK2 channel activity, by reducing TG excitability, may serve as a brake to prevent the pathological activation of TG neurons during the early stages of CSD. In patients expressing TRESK-MT, this mechanism may be reduced or eliminated, enhancing the activation of TG neurons, thus leading to migraines. Fitting the model in which an increase in TG excitability is the primary underlying cause of headaches, the TRESK-MT proband described in the original Lafreniè re paper (Lafreniè re et al., 2010; OMIM no. 613656 ) also showed migraine headaches in isolation without a preceding aura.
Most importantly, this study led us to uncover an undescribed mechanism involving alternative translation initiation. We provide evidence that the 2-bp deletion observed for TRESK-MT introduces an in-frame start codon with the reference open reading frame of TRESK, allowing the formation of MT2, the TRESK fragment responsible for the increase in TG excitability. Translation initiation of most eukaryotic mRNAs follows a linear scanning mechanism where the 40S ribosome is recruited to the 5 0 cap structure of the mRNA followed by downstream movement until an initiation codon is encountered (Kozak, 1999) . In these cases, the translation initiation site is the first cap-proximal start codon for methionine (AUG). In most eukaryotic mRNA, this first AUG is embedded into the Kozak consensus sequence [A/G]-XX-ATGG (Kozak, 1984a (Kozak, , 1984b Jackson et al., 2010) . However, if the first AUG is used inefficiently, some ribosomes read through the site without recognition; this leaky scanning can result in translation initiation at a downstream position (Thomas et al., 2008) . This has been observed for TREK1, where the second strong ATI site allows the physiological formation of a TREK1 channel with a shorter N terminus that leads to altered TREK1 ion selectivity (Thomas et al., 2008) . Similar to what was seen with TREK1, the TRESK ATG at position +356 is embedded into the Kozak consensus sequence (GCTATGG), which may explain why this ATG can serve as an ATI. To further determine why the ATG at position +356 is able to serve as an ATI, we submitted the TRESK-MT sequence to TIS Miner and the ATGpr algorithms (Nishikawa et al., 2000) , and both algorithms predicted that the ATG at position +356 is a strong start codon and it is the second possible start codon after ATG at position +1. Furthermore, we found that Kozak sequence mutation significantly reduced the TRESK-MT effect on TREK1 current. This indicates that leaky scanning may explain the generation of TRESK-MT2.
At the physiological level, ATI is thought to increase protein functional diversity, as is also the case with RNA splicing. For example, it was recently shown in osteogenesis imperfecta (OI) disease, that a causative missense mutation of c.-14C > T of the cDNA encoding IFITM5 creates an upstream ATG (ACG at position À15 was mutated to give ATG) in the 5 0 UTR in frame with IFITM5, which can serve as an ATI site, resulting in addition of an N-terminal 15-aa sequence (Lazarus et al., 2014) . Here, we find that an ATG embedded by a strong Kozak sequence, downstream of the ATG at position +1, can be put in frame by a frameshift mutation to induce the translation of a second truncated protein. In the present work, this second product was found to target TREK1 and TREK2 to increase TG neuron excitability and to produce mechanical allodynia, linking this mutant to migraine. This represents the first example where a frameshift mutation downstream of an ATG start codon at position +1 creates a new ORF, allowing the production of a second product that is at the origin of a physiological disturbance. To see whether this fsATI is a general phenomenon in TRESK, we predicted that any mutations before the stop codon ATG at position +427 that put the ATG at position +356 in frame would induce the formation of an MT2 that would lead to disease. Indeed, we demonstrate that another frameshift mutation, c.361dupT (Y121LfsX44), also leads to the formation of MT2 and is correlated to migraine (Clinvar, RCV000490385.1). It is not possible to make any causal statements from this observation, but it is worth noting that this is the only other TRESK mutation that has been linked to a migraine phenotype. Together, this work shows that different frameshift mutations downstream of the first start codon can lead to ATI to produce a second protein that can carry the physiological function, suggesting that this mechanism may be widespread in nature and therefore needs to be considered when analyzing frameshift mutations linked to human disorders.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: HEK cells HEK (human embryonic kidney) 293T cells were purchased from ATCC and maintained at 37 , in 5% CO 2 in high glucose DMEM containing 10% fetal bovine serum and used from passage 10 to 40. One splitting per week was made on 35 mm diameter dishes.
Xenopus oocytes
Xenopus leavis oocytes were collected from female Xenopus leavis (agreement # 35382015121816318324V7) and dissociated using collagenase type IV (Levitz et al., 2016) . Oocytes were injected with 50 nL of a cRNA at a concentration of 1mg/mL and maintained at 18 C in ND96 solution (96 mM NaCl, 2 mM KCl, 2 mM MgCl 2 , 1.8 mM CaCl 2 , 5mM HEPES, pH 7.4). Oocytes were used 1 to 3 days after injections.
Rats
Experiments were performed on male Sprague Dawley rats (Janvier Labs) weighing 250 to 400 g (mean weight: 337 ± 16 g, 6 to 9 weeks old), and on male knock-out mice for TREK1 and TREK2 (weighting 20-25 g 7-to 13-weeks-old 
WT mice
All mouse experiments were conducted according to national and international guidelines and have been approved by the local ethical committee (CIEPAL NCE). The C57BL/6J breeders were maintained on a 12 h light/dark cycle with constant temperature (23-24 C), humidity (45%-50%), and food and water ad libitum at the animal facility of Valrose.
METHOD DETAILS
Behavioral experiments Drug administration and virus injection
For the topiramate experiment, mice were injected intraperitonealy with topiramate once at a dose of 30 mg/kg and mechanical nociception thresholds were assessed every 30 minutes for two hours after the injection. The procedures of virus trigeminal injections are described by Long et al. (Long et al., 2017) . Briefly, following general anesthesia with a cocktail of ketamine and xylazine (100 mg/kg and 10 mg/kg respectively in i.p), rats were shaved on the right side, which is the injected side, and placed on a warmed surgical plate. The site of injection was determined using a notch between the condylar process and the ipsilateral angular process. The depth of injection was 9 mm. Antibiotics were used 5 days following injections. Viral vector suspension (10 mL, 10 11 transduction unit) containing 6 mg/mL of Polybrene was injected slowly over 1 min. Rats in the experimental group (randomly selected, n = 14) received 10 mL of viral vector containing the MT2 protein sequence, while those in the control group (randomly selected, n = 14) received the same amount of EGFP viral vector. Injections were made in a blind way for the behavior experimenter. Epifluorescence imaging and qPCR were performed to verify successful transduction of trigeminal ganglia by viral vector.
Mechanical sensitivity measurements
The face mechanical sensitivity was measured using calibrated von Frey filaments (Bioseb, France). Unrestrained rats placed in individual plastic boxes on top of a wire surface were trained over one week to stimulation on the periorbital area, following a progressive protocol, starting with non-noxious filaments during the first 3 days of training. The face withdrawal force threshold (g) was determined by the filament evoking at least three responses over five trials, starting with lower force filaments. Basal values were determined 2 days before experiments. Animals showing an outliner threshold for the basal value were excluded from the study.
The hindpaw mechanical sensitivity was evaluated with a dynamic plantar aesthesiometer (Ugo Basile, Italy). Unrestrained mice were placed in 10 individual plastic boxes on top of a wire surface. The mouse hindpaw was submitted to a force ramp up to 7.5 g during 10 s, the paw withdrawal force threshold (g) was assessed in three consecutive trials with at least 3-5 min between the trials and averaged to select animals. Basal values were determined 2 days before experiments. Animals showing an outliner threshold for the basal value were excluded from the study.
Migraine rodent models
The rodent model of NO-induced migraine was induced by intraperitoneal (i.p.) injection of ISDN (RisordanÒ, Sanofi) at 10mg/kg, a long-lasting NO donor. The vehicle control used in these experiments was 0.9% saline. The acute mechanical allodynia induced by a single ISDN injection was followed on the hindpaw for mice and on the face for rats before (basal value) and for 3 hours after injection, every 30 minutes. Animals showing an outliner threshold for the basal value were excluded from the study. Chronic mechanical allodynia was induced by a single daily injection of ISDN during 4 days. The hindpaw extra-cephalic mechanical sensitivity was measured each day before the ISDN i.p. injection for mice. Topiramate was tested on chronic mechanical allodynia on the 5th day and effects were followed every 30 min during 2 hours after injection in mice. Experiments were made on two batches of animals in duplicate.
Single Molecule Pulldown (SiMPull)
For SiMPull experiments, a DNA ratio of 1:1 was used, with a total quantity of 1 mg. 24 hours after transfection, HEK 239T cells were harvested from coverslips by incubating with Ca 2+ -free PBS buffer for 20-30 minutes followed by gentle pipetting. Cells were lysed in buffer containing (in mM): 150 NaCl, 10 Tris pH 7.5, 1 EDTA, protease inhibitor cocktail (Thermo Scientific) and 1.5% IGEPAL (Sigma) or 1% DDM (Sigma). After 30-60 minute incubation at 4 , lysate was centrifuged for 20 minutes at 12,500 g and the supernatant was collected. Coverslips passivated with PEG ($99%)/ biotin-PEG ($1%) and treated with NeutrAvidin (Pierce) were prepared as described (Jain et al., 2012) . 15 nM biotinylated anti-HA antibody (clone 16B12, BioLegend) was applied for 20 minutes and then washed out. Antibody dilutions and washes were done in T50 buffer with BSA containing (in mM): 50 NaCl, 10 Tris pH 7.5, and 0.1 mg/mL BSA. Lysate, diluted in lysis buffer containing 0.04% IGEPAL, was then applied to the chamber and washed away following brief incubation ($2 minutes). Single molecules were imaged using a 488 nm Argon laser on a total internal reflection fluorescence microscope with a 60x objective (Olympus). We recorded the emission light after an additional 3x magnification and passage through a double dichroic mirror and an emission filter (525/50 for GFP) with a back-illuminated EMCCD camera (Andor iXon DV-897 BV). Recordings were made in blind for the experimenter before being analyzed.
Single cell reverse transcription
The procedures of single cell RT-PCR are adapted from Johansen et al. (Johansen et al., 1995) . The content of each cell was aspirated into the patch pipette by applying negative pressure. The flow of the cytosol in the pipette as well as the aspiration of the nucleus was controlled under the microscope. Only cell samples which included the nucleus were investigated in the present study.
The pipette was then released from the holder and mounted on a syringe to expel its content into a test tube. To the $6.5 mL of the pipette-content expelled into the test tube was added 3.5 mL of a solution containing random hexamers (Invitrogen, 5 mM final concentration), dithiothreitol (DTT, final concentration 10 mM), the four deoxyribonucleotide triphosphates (dNTP, Thermo Fisher, final 0,5 mM each), 20 U ribonuclease inhibitor (Promega), and 100 U Moloney murine leukemia virus reverse transcriptase (Invitrogen).
The total 10 mL reaction was incubated for 1h at 35 C for synthesis of single stranded cDNA, and then kept on ice until PCR.
Trigeminal neurons RNA extraction and reverse transcription Total RNA was isolated from trigeminal neurons in suspension using a Nucleospin RNA Plus XS kit (from MACHEREY-NAGEL GmbH & Co. KG) according to the manufacturer's protocols and 1 mg of RNA was reverse transcribed (with 10 nM random hexamers for 5 min at 65 C, then with 10 mM DTT, 0.5 mM each dNTP, 100 U SuperScript II (Invitrogen) 42 C for 50 min). Subsequently, the cDNA was quantified by qPCR with PowerUp SYBR Green Master Mix (ThermoFisher).
Vector preparation
Adenovirus vector (DJ) encoding an IRES2EGFP or MT2-IRES2EGFP were used. Following linearization, this vector was recombined with the mouse version of the MT2 protein. The recombinant was amplified with PCR, and DNA sequencing was performed to verify the DNA sequence. Viral vectors were packaged and harvested by transfection of HEK293T cells, followed by quantification of the viral titer through quantitative PCR. In addition, as a control, an adenovirus vector containing only the IRES2EGFP sequence was used.
Western blot analysis 24 to 48 hours after transfection using 1mg DNA with Lipofectamine 2000, HEK293T cells were homogenized in PBS containing saponin (0.5% w/v), Triton X-100 (0.5% w/v) and protease inhibitors (Roche Diagnostics, Basel, Switzerland). Lysates were clarified by centrifugation at 20 000 g for 30 min. Proteins were separated on 10% SDS polyacrylamide gel and blotted onto nitrocellulose membrane (Hybond-C extra, Amersham Biosciences, Freiburg, Germany). Detection was carried out using mouse monoclonal antibody clone HA-7 against the HA epitope (Sigma-Aldrich).
QUANTIFICATION AND STATISTICAL ANALYSIS
Single Molecule Pulldown
Movies of 250-500 frames were acquired at frame rates of 10-30 Hz. The imaged area was 13 3 13 mm 2 . At least 5 movies were recorded for each condition and data was analyzed using custom software. Multiple independent experiments (at least 3 times) were performed for each condition. Representative datasets are presented to quantitatively compare conditions tested on the same day.
Electrophysiology
The numbers of cells tested are indicated in parentheses on top of graphs in each figure. Cells come from at least 3 batches of experiment. Student's t test (*p < 0.05, **p < 0.01, ***p < 0.001) are performed between the different conditions tested (indicated in each figure's legend). For neurons, the cells come from at least 4 different animals. When the data did not follow a normal distribution, Mann-Whitney U test were assessed.
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Animal experiment
Numbers of mice and rats tested are indicated in parentheses in each figure. Student's t test to compare WT versus TREK1 À/À / TREK2 À/À mice (*p < 0.05, **p < 0.01, ***p < 0.001).
Quantitative PCR Analysis were made using the GAPDH as the housekeeping gene along with the 2-DDCt Calculation Method. n represents the number of single cells tested.
